Categories: Health

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Taysha Gene Therapies, Inc.

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha’s Board of Directors granted one new employee an option to purchase 90,000 shares of the Company’s common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $2.63 which is equal to the closing price of Taysha’s common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee’s continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

GlobeNews Wire

Recent Posts

Drivio Play Offers Affordable Car Tech Upgrade in 2025: Portable Infotainment System Brings Navigation, Streaming, and Hands-Free Safety Features to Older Vehicles

Detroit, Aug. 23, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only.…

1 hour ago

MaxgenBit: This MaxgenBit Trading Platform Sets New Standard in AI-Driven Trading with Unmatched Security and UK User Approval For ROI

London, UK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- MaxgenBit today announced its emergence as a…

1 hour ago

Comviva Wins Gold at Brandon Hall Group HCM Excellence Awards 2025 for Learning and Development

Recognized in the 'Best Learning Strategy' category for building a future-ready, AI-powered workforce NEW DELHI,…

6 hours ago

Aghanim Unveils Checkout 2.0, Kinetic Framework & More to Power the Future of Game Commerce

Aghanim - a fast-growing fintech organization with over 250 web-based game hubs, built using its…

6 hours ago

TACC Limited and CRRI Collaborate to Revolutionize Indian Infrastructure with Graphene-Enhanced Pavements

NEW DELHI, Aug. 21, 2025 /PRNewswire/ -- TACC Limited has signed a Memorandum of Agreement (MoA)…

7 hours ago

DXC Named a Leader in Everest Group’s Custom Application Development Services PEAK Matrix Assessment 2025 Report

Report highlights DXC's strengths leveraging GenAI platforms, equipping software engineers with secure AI-powered assets and…

7 hours ago